Introduction Melatonin plays fundamental roles in diverse physiological functions ranging from the regulation of circadian rhythms to tumor inhibition, owing to its antioxidant, immunomodulatory and anti-aging properties1-3. The therapeutic potential of melatonin and its analogues4,5 prompted us to investigate the in vitro and in vivo antitumor activity of new melatonin derivatives on melanoma and breast cancer cells, and explore the underlying molecular mechanisms. Materials and methods New indole melatonin analogues were synthetized and tested for their ability to inhibit proliferation and induce apoptosis in DX3 melanoma cells and in MCF-7 and MDA-MB231 breast cancer cells by viability and apoptosis assays. The oncostatic effect of melatonin analogues was also measured on a human melanoma xenograft mouse model. The changes in the expression levels of different proteins in cancer cell lines during treatment with melatonin analogues were investigated by Western blot analysis. Results The experiments revealed that the new melatonin analogues inhibited the growth of DX3 melanoma cells in a dose- and time-dependent manner. In addition, the study demonstrated that low concentrations (0.1 mM) of the melatonin analogue UCM 1037 exhibited antiproliferative and cytotoxic effects also in MCF-7 and MDA-MB231 breast cancer cells. The suppression of DX3 tumor growth by the melatonin analogues was further demonstrated in vivo in a xenograft mice model. Caspase 3 resulted to be involved in the pro-apoptotic mechanism induced by UCM 1037 in DX3 and MDA-MB231 cells. A decrease in the activation of both Akt and MAPK pathways was observed in breast cancer cells following UCM 1037 treatment. Conclusions This study describes melatonin derivatives showing promising antiproliferative and cytotoxic activity in melanoma and breast cancer cells. References and acknowledgements 1. Cutando et al. Anticancer Res 2012;32:2747-2753. 2. Su et al. J Pineal Res 2017;62:e12370. 3. Reiter et al. Physiology 2014;29:325-333. 4. Kostiuk et al. ISRN Biochem 2014;2014:843478. 5. Liu et al. Annu Rev Pharmacol Toxicol 2016;56:361-383. A.B. is supported by a grant from Fondazione Cariplo-Regione Lombardia.

Anticancer activity of melatonin analogues

Bevilacqua A
2017-01-01

Abstract

Introduction Melatonin plays fundamental roles in diverse physiological functions ranging from the regulation of circadian rhythms to tumor inhibition, owing to its antioxidant, immunomodulatory and anti-aging properties1-3. The therapeutic potential of melatonin and its analogues4,5 prompted us to investigate the in vitro and in vivo antitumor activity of new melatonin derivatives on melanoma and breast cancer cells, and explore the underlying molecular mechanisms. Materials and methods New indole melatonin analogues were synthetized and tested for their ability to inhibit proliferation and induce apoptosis in DX3 melanoma cells and in MCF-7 and MDA-MB231 breast cancer cells by viability and apoptosis assays. The oncostatic effect of melatonin analogues was also measured on a human melanoma xenograft mouse model. The changes in the expression levels of different proteins in cancer cell lines during treatment with melatonin analogues were investigated by Western blot analysis. Results The experiments revealed that the new melatonin analogues inhibited the growth of DX3 melanoma cells in a dose- and time-dependent manner. In addition, the study demonstrated that low concentrations (0.1 mM) of the melatonin analogue UCM 1037 exhibited antiproliferative and cytotoxic effects also in MCF-7 and MDA-MB231 breast cancer cells. The suppression of DX3 tumor growth by the melatonin analogues was further demonstrated in vivo in a xenograft mice model. Caspase 3 resulted to be involved in the pro-apoptotic mechanism induced by UCM 1037 in DX3 and MDA-MB231 cells. A decrease in the activation of both Akt and MAPK pathways was observed in breast cancer cells following UCM 1037 treatment. Conclusions This study describes melatonin derivatives showing promising antiproliferative and cytotoxic activity in melanoma and breast cancer cells. References and acknowledgements 1. Cutando et al. Anticancer Res 2012;32:2747-2753. 2. Su et al. J Pineal Res 2017;62:e12370. 3. Reiter et al. Physiology 2014;29:325-333. 4. Kostiuk et al. ISRN Biochem 2014;2014:843478. 5. Liu et al. Annu Rev Pharmacol Toxicol 2016;56:361-383. A.B. is supported by a grant from Fondazione Cariplo-Regione Lombardia.
2017
Melatonin; Melatonin receptors; Melatonin analogues; Melanoma; Breast cancer
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12078/2601
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact